Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the Treatment of Chronic AsthmaA Multicenter, Randomized, Double-blind Trial

Open Access
Publisher Website
Google Scholar
Abstract
ASTHMA IS a significant worldwide health problem, accounting for $4.2 billion of health care costs in the United States in 1995.1 Despite the development and institution of treatment guidelines,2 asthma remains a costly clinical problem, with a continuous need for new, innovative treatments. Current therapies have limitations, including poor compliance (inhalers, dosage frequency) and side effects.3 New, effective, well-tolerated oral therapies may have a substantial impact on the management of asthma.